Overview

Dashboard News

Air France KLM faces challenges from proposed airline tax increases

UBS anticipates that Air France-KLM will be impacted by higher airline taxes, affecting nearly 80% of its network, which accounts for 46% of the group's overall operations. While it is uncertain how the airline will adjust its capacity, increased taxation may lead to reduced air traffic demand in France, potentially prompting a shift to its Amsterdam hub or smaller aircraft on certain routes. The broker maintains a Buy rating with a price target of €12.75.
ABC Bourse
Euro Air France-KLM SA FRA
TradFi, Market Report
14:30 14.10.2024

DAX poised for record high amid ECB meeting and US earnings season

The DAX is nearing record highs as the ECB meeting and US earnings season approach. Key events include the ZEW index release, with expectations of an increase, and potential ECB rate cuts. US retail sales and unemployment claims will also be closely monitored, alongside significant data from China and major US bank earnings reports.
IG
Euro Chinese Yuan United States Dollar The Goldman Sachs Group, Inc. The Procter & Gamble Company American Express Company Bank of America Corporation Morgan Stanley Citigroup Inc. DEU CHN USA American Express Netflix Morgan Stanley Procter & Gamble Christine Lagarde Show more
TradFi, Market Report
14:18 14.10.2024

fda reviews zepbound and mounjaro amid ongoing drug shortage disputes

The FDA has temporarily halted a lawsuit regarding the removal of Eli Lilly’s Zepbound and Mounjaro from its shortage list, agreeing to reassess the situation amid strong demand for GLP-1 medications. Compounded versions of tirzepatide can continue to be sold while negotiations with the Outsourcing Facilities Association proceed. The FDA previously declared that manufacturing capacity now meets national demand, but the OFA argues this decision violated federal law by not following proper procedures.
BioPharma Dive
United States Dollar Eli Lilly and Company Novo Nordisk A/S USA Show more
Regulatory & Legal, News Article
14:18 14.10.2024

lundbeck acquires longboard pharmaceuticals for 2.6 billion dollars to enhance brain drug portfolio

Danish drugmaker Lundbeck has agreed to acquire Longboard Pharmaceuticals for $2.6 billion, paying $60 per share, a 54% premium. The deal aims to enhance Lundbeck's portfolio with bexicaserin, a potential treatment for developmental and epileptic encephalopathies, which could generate annual sales of $1.5 billion to $2 billion. The acquisition is expected to close by year-end, positioning Lundbeck for growth as it faces patent expirations on key products.
BioPharma Dive
United States Dollar H. Lundbeck A/S Arena Pharmaceuticals Inc. Longboard Pharmaceuticals, Inc. Pfizer Inc. DNK Charl van Zyl Arena Pharmaceuticals Show more
Finance & Economy, Market Report
14:14 14.10.2024

ubs faces opposition in us pension fund dealings amid legal challenges

UBS is facing opposition from tax activists regarding its dealings with US pension funds, as it seeks an extension of a prohibited transaction exemption. Concerns have been raised about the bank's history of criminal behavior, with UBS having paid around $20 billion in penalties for nearly 100 offenses since 2000. Following its acquisition of Credit Suisse, UBS also inherited ongoing legal issues, including a conviction related to organizational deficiencies at Credit Suisse.
finews.ch
United States Dollar DoJ Credit Suisse Anlagestiftung UBS SA FRA BGR USA CHE James Henry Reuters Show more
TradFi, News Article
14:07 14.10.2024

GSK reports positive Phase 3 results for chronic nasal condition drug

GSK announced positive results from two Phase 3 trials of its antibody drug depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP), showing significant suppression of nasal polyp growth and improved nasal obstruction compared to placebo. The drug, which targets IL-5, is also being studied for asthma and other inflammatory diseases, with potential peak annual sales exceeding £3 billion if approved. Detailed trial results will be presented at an upcoming scientific congress.
BioPharma Dive
British Pound Sterling Sanofi Regeneron Pharmaceuticals, Inc. Glaxosmithkline Export Ltd. GBR USA Kaivan Khavandi Show more
Healthcare, News Article
14:01 14.10.2024

us stock market poised for gains amid strong profit growth and economic stability

US equities are poised for further gains, with the S&P 500 recently reaching its 45th all-time high this year, driven by healthy profit growth. Despite expected volatility during the earnings season, a solid economic backdrop and a favorable outlook for corporate profits, particularly in AI, support a positive market sentiment. The S&P 500 earnings per share growth is projected at 5-7% for the September quarter, with a full-year forecast of 11%, as the Federal Reserve's rate-cutting cycle is expected to bolster economic activity.
Insights
United States Dollar Apple Inc. Federal Reserve Bank of Boston N.A. USA
TradFi, Market Report
13:59 14.10.2024

growth of self-employment and franchising in the french economy

Franchising in France has seen significant growth, with 92,132 outlets generating €88.49 billion in sales and creating nearly 1 million jobs. Franchisees operate independently while benefiting from established brands and support, with average earnings around €35,325 annually. Profitable sectors include healthcare, corporate services, and real estate, offering lucrative opportunities for self-employed individuals.
Observatoire de la franchise
Euro Safti Sàrl SCI Capifrance AXA SA FRA Show more
Finance & Economy, Market Report
13:58 14.10.2024

Pfizer's Hympavzi receives FDA approval for hemophilia treatment options

The FDA has approved Pfizer's Hympavzi for treating hemophilia A and B in patients aged 12 and older without inhibitors. This weekly injection reduces the activity of tissue factor pathway inhibitor, enhancing blood clotting. Hympavzi offers a new treatment option alongside gene therapies and other factor replacement drugs, showing superior results in lowering bleeding rates.
BioPharma Dive
United States Dollar Pfizer Inc. CSL Behring BioMarin Pharmaceutical Inc. Hoffmann-La Roche AG Sanofi USA Starboard Value Aamir Malik Show more
Healthcare, News Article
13:45 14.10.2024

Lumen Vietnam Fund optimistic about stock market growth through 2025

Lumen Vietnam Fund maintains a positive outlook for the Vietnamese stock market through late 2024 and into 2025, driven by global monetary easing and optimistic domestic economic forecasts. The Vietnamese government’s regulatory reforms and proactive measures are expected to enhance investor confidence and corporate earnings, while the fund continues to focus on a diversified portfolio across key sectors. In September, the fund recorded a 1.58% return, aligning closely with the VN-Index's performance.
theinvestor.vn
Vietnamese Đồng United States Dollar Shinhan Bank Vinhomes Citigroup Inc. HSBC Holdings plc CHN VNM VAT Joe Biden Donald Trump Show more
TradFi, Market Report
13:13 14.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Cryptocurrency & Blockchain Regulations Central Bank Actions Market Sentiment Analysis Banking & Investment Regulations Employment Reports Banking Regulations Corporate Responsibility & ESG Anti-Money Laundering (AML) Regulations Inflation Rates & CPI Data Blockchain Technology Adoption Hedge Funds & Private Equity Cryptocurrency Regulations Tokenomics and Crypto Economics Decentralized Finance (DeFi) Innovations Mergers & Acquisitions Emerging Startups Cryptocurrency Developments
Countries:
USA GBR CHE DEU RUS IND CHN CAN ARE FRA JPN SGP TWN ESP MYS BRA LUX KEN THA AUS
Companies:
Coinbase Global, Inc. Apple Inc. NVIDIA Corporation Solana USD Ethereum USD Tesla, Inc. Chainlink USD Bitwise Bitcoin ETF Fidelity Contrafund UBS Group AG BlackRock, Inc. MicroStrategy Inc Delta Air Lines, Inc. Kraken Energy Corp. Ripple USD USD Ripples USD Microsoft Corporation Standard Chartered PLC Novartis AG Bank of America Corporation
Currencies:
United States Dollar Euro Swiss Franc British Pound Sterling Japanese Yen Indian Rupee Swedish Krona Chinese Yuan Canadian Dollar Singapore Dollar South Korean Won New Taiwan Dollar Thai Baht Philippine Peso Russian Ruble Vietnamese Đồng
People:
Donald Trump Elon Musk Ali Martinez Cynthia Lummis Gary Gensler Joe Biden Paul Atkins Brad Garlinghouse Bill Hughes Sr Tim Scott Matt Hougan Jerome Powell Bernie Moreno Elizabeth Warren Laurent Marochini Margaret Harwood-jones Keith Ammon James Howells Jimmy Carter Dave McCormick

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings